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Abstract
A gram-scale enantiospecific synthesis of the A’B’-subunit of angelmicin B is reported. The
synthesis involves a Lewis acid-catalyzed contrasteric Diels–Alder reaction and a tandem silyl
zincate 1,6-addition/enolate oxidation sequence.
Angelmicin B (1, Figure 1) was isolated in 1993 by Uehara, Oki, and coworkers from the
rare actinomycete Microbispora subsp. AA9966.1,2 Hibarimicin B, which was subsequently
isolated along with hibarimicin A-G from the Microbispora rosea subsp. hibaria TP-A0121,
shares an identical structure with 1. Angelmicin B (1) was originally identified as an
inhibitor of Src tyrosine kinase (IC50 > 5800 nM),1a and was later found to inhibit
proliferation and induce differentiation of HL-60 human leukemia tumor cells (IC50 = 58
nM).3 The discrepancy between these effective concentrations suggests that Src is perhaps
not the target responsible for the anticancer activity of 1, and to date, the cellular target of 1
remains unidentified.
Angelmicin B (1) is a pseudo-C2-symmetric glycosylated type II polyketide. The two halves
of its fascinating pseudo-C2-symmetric structure differ in the oxidation states of the B/B’, C/
C’, and D/D’ rings. Several questions concerning the absolute and relative configuration of 1
remain to be addressed.4 The absolute configuration of both halves of the aglycon and the
carbohydrates as well as the relative stereochemistry of the C13′-carbinol are unknown.
Additionally, it is unclear whether the compound exhibits atropisomerism as a result of
potential hindered rotation about its C2–C2′ bond.5 A total synthesis of 1 or its aglycon
would elucidate these stereochemical uncertainties, but has yet to be achieved.6 Intrigued by
the biological properties, stereochemical ambiguities, and structural complexity of 1, we
initiated a program aimed at its total synthesis. Herein we report a highly scalable
enantiospecific synthesis of the orthogonally protected A’B’-subunit of angelmicin B (2,
Scheme 1).
Our retrosynthesis of 2 is outlined in Scheme 1. We anticipated that the enone functionality
in 2 could be generated by oxidation of allylic silane 3. Additionally, we envisioned that
introduction of the n-propyl substituent in 2 could be accomplished through a
diastereoselective organometallic addition to α-hydroxy ketone 3 from the convex face of
the rigid cis-decalin carbon framework. Next, compound 3 would be accessed by means of a
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regio- and diastereoselective 1,6-addition of a silyl zincate to dienone 4, followed by in situ
oxidation of the resultant extended zinc enolate. A Lewis acid-catalyzed contrasteric Diels–
Alder reaction between cyclohexenone 5 and 1,3-butadiene would then set the relative
stereochemistry in 4, wherein the newly formed C–C bonds and the C4–OTBS substituent
reside in a syn orientation. Finally, suitably protected cyclohexenone 5 would be prepared
through ring-closing metathesis of a linear precursor accessed from readily available D-
glucose derivative 6. The type and position of the hydroxyl protecting groups were chosen
with respect to two criteria. First, a C4–OTBS group was deemed necessary for syn
selectivity in the key Lewis acid-catalyzed contrasteric Diels–Alder reaction. Second,
orthogonally deprotectable groups were selected to facilitate sequential introduction of the
sugar residues surrounding angelmicin B. The ability to produce gram quantities of late-
stage intermediates is essential for a successful total synthesis of angelmicin B, one of the
largest and most complex aromatic polyketides known. Recognition of the common
stereochemical elements shared by 2 and D-glucose helped enable the realization of this
requirement.
Our synthesis commenced with compound 6, which was obtained in three steps from methyl
α-D-glucopyranoside on multigram scale according to a modified literature protocol
(Scheme 2).7 A three-step procedure for the conversion of 6 to iodide 7 began with AcOH-
mediated hydrolysis of the benzylidene acetal, followed by selective Wittig iodination of the
resultant primary hydroxyl group and TBS protection of the remaining secondary carbinol in
90% overall yield. Sonication of 7 with activated zinc powder promoted reductive
fragmentation to generate an aldehyde intermediate,8 which upon treatment with an
organocerium reagent derived from vinylmagnesium bromide furnished allylic alcohol 8 as
an inconsequential diastereomeric mixture in 75% yield over two steps.9,10 Finally, exposure
of 8 to first-generation Grubbs olefin metathesis catalyst11 in dilute CH2Cl2 followed by
Parikh–Doering oxidation12 of the resulting diastereomeric cyclohexenols produced
cyclohexenone 5 in 82% yield over two steps. Over thirty grams of 5 was prepared through
this method.
Following our synthesis of 5, we next attempted the key Lewis acid-catalyzed contrasteric
Diels–Alder reaction depicted in eq 1 of Scheme 3. Danishefsky and coworkers had
previously demonstrated that 2-cyclohexenone 9, bearing a γ-OTBS group, participates in a
contrasteric intermolecular Diels–Alder reaction with 1,3-butadiene when catalyzed by
AlCl3 to provide cis-decalin 10 in 76% yield (eq 1, Scheme 3).13 In this transformation, the
β-C–C bond is formed syn relative to the γ-OTBS group in high diastereoselectivity (>10:1
syn:anti). We anticipated similar stereoselectivity in our proposed Diels–Alder reaction,
despite the additional Lewis basic groups in our substrate. Gratifyingly, treatment of 5 with
1,3-butadiene in the presence of TiCl4 at 5 °C for 3.5 h afforded a >10:1 mixture of adducts,
favoring the desired syn diastereomer 11. This reaction, which can be performed on
multigram scale with high diastereoselectivity, is to our knowledge the most complex
example of a contrasteric Diels–Alder yet reported.
The stereoselectivity of this reaction is likely governed by subtle steric and stereoelectronic
effects. Approach of 1,3-butadiene to 5 syn to the γ-OTBS substituent is sterically occluded
by both the γ-OTBS and α-OPiv groups and thus counterintuitive (transition state 1, Scheme
3). However, stereoelectronic considerations suggest that pseudo-axial approach of 1,3-
butadiene to the β-carbon of the chair-like ground state conformation of 9 is kinetically
favored.14 Additionally, the Cieplak model has been invoked to rationalize the
stereochemical outcome for the aforementioned Diels–Alder reaction.15 In accordance with
this line of reasoning, formation of the β-C–C bond syn with the electron-withdrawing γ-
OTBS group stabilizes the forming σ*-C–C orbital through hyperconjugation with the
electron-donating σ-C–H bond (transition state 2, Scheme 3). It is plausible that a synergism
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of individually small stereoelectronic effects bias the reaction pathway towards the observed
product diastereomer 11.
The synthesis of 2 continued with a series of carefully controlled oxidations of the cis-
decalin carbon skeleton of 11 (Scheme 4). Exposure of 11 to TMSI, generated in situ from
TMSCl and NaI, promoted thermodynamic enolization of the ketone at C6 rather than at C2
to generate enol silane 12 as a single regioisomer.16 This regioselection is particularly
noteworthy since C2–H is presumably more acidic than C6–H. Chemoselective oxidation of
12 was accomplished upon treatment of 12 with DDQ to afford dienone 4 in 78% overall
yield, again as a single regioisomer.17 The mild nature of this procedure prevented over-
oxidation of the dienone moiety. Next, regio- and diastereoselective addition of
dimethylphenylsilyl zincate to the δ-position of dienone 4 generated extended zinc enolate
intermediate 13.18 In situ α-oxidation of 13 with MoO5•pyr•HMPA (MoOPH) delivered cis-
decalin 3 as a single regio- and diastereoisomer in 82% yield. The one-pot 1,6-conjugate
addition/enolate oxidation sequence was amenable to a variety of oxidants including Davis
oxaziridine and DMDO; however, MoOPH proved the most efficient oxidant on large-
scale.19 Overall, the tandem reaction sequence generated the sterically congested C6-tertiary
carbinol and an allylic silane, which was planned to serve as a latent enone surrogate.
Exposure of 3 to excess organocerium reagent derived from n-propylmagnesium chloride
led to carbonyl addition exclusively from the convex face of the molecule and concurrent
cleavage of the pivoyl ester (Scheme 4).20 The use of a mixed organocerium reagent was
required to avoid ketone enolization and reduction.21 The resultant 1,2-diol was protected as
an acetonide, affording 14 in 71% yield over two steps. Treatment of 14 with m-CPBA led
to epoxidation of the allylic silane with in situ 1,5-silyl migration of silicon and concomitant
epoxide opening to provide compound 15 in 85% yield.22 Chemoselective removal of the
dimethylphenylsilyl group with TBAF at −78 °C and Swern oxidation23 of the resulting
allylic alcohol delivered 2 in 91% yield over two steps on gram-scale, completing our
synthesis of the protected A’B’-subunit of angelmicin B.
In summary, a scalable and enantiospecific synthesis of the protected A’B’-subunit of
angelmicin B (2) has been accomplished starting from methyl α-D-glucopyranoside. This
sequence has been utilized to prepare 3.2 grams of 2 to date. The synthesis features a Lewis
acid-catalyzed contrasteric Diels–Alder reaction between cyclohexenone 5 and 1,3-
butadiene. Additionally, the synthesis further demonstrates the utility of silyl zincate
reagents in organic synthesis through their application in a tandem 1,6-conjugate addition/
enolate oxidation sequence. Reports of our progress toward a total synthesis of angelmicin B
will be forthcoming.
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Figure 1.
Structure of angelmicin B (1)
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Scheme 1.
Proposed Synthesis of 2
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Scheme 2.
Synthesis of Diels–Alder Substrate 5a
a Reagents and conditions: (a) 80% aq AcOH, 80 °C, 1 h, 94%; (b) Ph3P (1.3 equiv),
imidazole (3.0 equiv), I2 (1.3 equiv), PhMe, 23 to 45 °C, 1 h, 97%; (c) TBSOTf (2.0 equiv),
2,6-lutidine (1.0 M), 0 to 23 °C, 30 min, 99%; (d) Zn(0) (10 equiv), THF/H2O (4:1),
sonication, 40 °C, 2 h; (e) CH2CHMgBr (1.2 equiv), CeCl3 (1.2 equiv), THF, −78 °C, 2 h,
75% (3:1 dr) for two steps; (f) Grubbs I (5 mol %), CH2Cl2, 23 °C, 18 h, 85%; (g) SO3•pyr
(3.0 equiv), i-Pr2NEt (5.0 equiv), DMSO (10.0 equiv), CH2Cl2, 0 °C, 1.5 h, 97%.
Abbreviations: TBS = tert-butyldimethylsilyl, Grubbs I =
bis(tricyclohexylphosphine)benzylidine ruthenium(IV) dichloride, DMSO = dimethyl
sulfoxide, pyr = pyridine.
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Scheme 3.
Lewis Acid-Catalyzed Contrasteric Diels–Alder Reactiona
a Reagents and condtions: (a) 1,3-butadiene (20 equiv), AlCl3 (0.9 equiv), PhMe, 23 °C, 1 h,
76% (>10:1 syn:anti ). (b) 1,3-butadiene (8.0 equiv), TiCl4 (1.0 equiv), PhMe, −78 to 5 °C,
3.5 h, 76% (>10:1 syn:anti). Abbreviations: TS = transition state.
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Scheme 4.
Completion of the Synthesis of the A’B’-Subunit of Angelmicin B (2)a
a Reagents and conditions: (a) TMSCl (10 equiv), NaI (15 equiv), HMDS (20 equiv),
MeCN, 82 °C, 3 h; (b) DDQ (3.0 equiv), CH2Cl2, 23 °C, 3 h, 78% for two steps; (c)
Me2PhSiLi (1.0 M in THF, 1.5 equiv), ZnEt2 (1.0 M in PhMe, 1.5 equiv), THF, −78 °C, 30
min; then 4, −78 to 0 °C, 30 min; then MoOPH (2.6 equiv), −78 to −20 °C, 20 min, 82%;
(d) CeCl3 (15 equiv), LiCl (30 equiv), THF, 23 °C, 12 h; then n-PrMgCl (1.6 M in Et2O, 12
equiv), −78 °C, 3 h; then 3, −78 to 0 °C, 2 h, 85%; (e) 2-methoxypropene (10 equiv), PPTS
(10 mol %), PhH, 23 °C, 4.5 h, 84%; (f) m-CPBA (1.3 equiv), NaHCO3 (3.0 equiv),
CH2Cl2, −78 to −5 °C, 7 h, 85%; (g) TBAF (1.0 M in THF, 1.5 equiv), THF, −78 °C, 1.5 h,
99%; (h) (COCl)2 (8.0 equiv), DMSO (16 equiv), CH2Cl2, −78 °C, 1 h; then diol, −78 °C, 4
h; then Et3N (32 equiv), −78 to 0 °C, 30 min, 92%. Abbreviations: TMS = trimethylsilyl,
DDQ = 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone, MoOPH =
Oxodiperoxymolybdenum(pyridine)(hexamethylphosphoric triamide), PPTS = pyridinium
p-toluenesulfonate, m-CPBA = meta-chloroperbenzoic acid, TBAF = tetrabutylammonium
fluoride.
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